Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.
News
The Sales Awards: Finalists announced as countdown to awards evening begins!
All of the finalists competed in real life challenges that were devised by senior leaders in Sales. The contestants used their insightful knowledge and charisma in a bid to be announced as the winner on the 15th November.
The PharmaTimes International Clinical Researcher of the Year – The Americas competition is now open for entry!
Designed to recognise and reward the talent and passion of industry and academic researchers, The PharmaTimes Clinical Researcher of the Year – The Americas is open to give contestants the ultimate challenge. A valuable learning and development opportunity for clinical researchers in pharma, clinical research organisations (CROs) and investigator sites who currently work in North, South and Central America.
US expands reach of Keytruda in NSCLC
US regulators have approved MSD’s Keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
The Creative Floor Awards winners announced
Area23 and McCann Health win big
BHF urges heart patients to get flu jab
The British Heart Foundation is urging people with heart and circulatory disease to get vaccinated against the flu.
Long-term data backs safety and efficacy of GSK’s Nucala
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control in patients taking its biologic Nucala.
Marketer of the Year: Finalists announced as countdown to awards evening begins!
All of the finalists competed in real life challenges that were devised by senior Marketing leaders. The contestants used their insightful knowledge and charisma in a bid to be announced as the winner(s) on the 15th November.
FDA advisors turn down Alkermes’ ALKS 5461
Alkermes’ ALKS 5461 has been hit with a potential setback in the US after regulatory advisors failed to back its approval for major depressive disorder (MDD).
Sanofi buys into Denali’s RIPK1 programme
Sanofi is linking with Denali Therapeutics on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
ViiV’s fostemsavir shows promise in ‘heavily pre-treated’ HIV patients
ViiV Healthcare’s first-in-class attachment inhibitor fostemsavir has shown promise as a treatment for heavily pre-treated HIV patients failing on current antiretroviral regimens.
EU approves Vertex’ cystic fibrosis combo
The European Commission has approved Vertex’ Symveki in a combination regimen with Kalydeco to treat certain patients with cystic fibrosis (CF).
GSK narrows earnings guidance after Shingrix boost
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic competition for one of its key products.
Communications Team of the Year: Finalists announced as countdown to awards evening begins!
All of the finalists competed in real life challenges that were devised by senior communications leaders. The teams used their insightful knowledge and charisma in a bid to be announced as the winners on the 15th November.
